Abstract
Chemotherapy produces approximately a 30% long-term disease-free survival in newly diagnosed children with acute nonlymphocytic leukemia (ANLL). Al-though 75%–80% of children will enter a complete remission (CR), most will relapse with resistant leukemia while receiving postremission chemotherapy.
Supported by NIH grant CA-20180 and by the American Lebanese Syrian Associated Charities (ALSAC). Dr. Mirro is a recipient of a Clinical Oncology Career Development Award from the American Cancer Society
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dahl GV, Kalwinsky DK, Murphy SB, Look AT, Amadori S, Kumar M, Novack R, George SL, Mason C, Mauer AM, Simone JV (1982) Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. Blood 60: 856–863
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E (1980) Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303: 473–478
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD (1983) Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 62: 315–319
Dahl GV, Kalwinsky DK, Mirro J, Look AT (1987) A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia. Hamatol Bluttransfus 30: 83–87
Kalwinsky DK, Dahl GV, Mirro J, Jackson CW, Look AT (1986) Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol 14: 245–250
Look AT, Dahl GV, Kalwinsky D, Senzer N, Mason C, Rivera G (1981) Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16–213 plus azacitidine. Cancer Treat Rep 65: 995–999
Kalwinsky DK, Mirro J, Schell M, Behm F, Mason C, Dahl GV (1988) Early intensification of chemotherapy for childhood acute nonlymphocytic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol 6: 1134–1143
Büchner TH, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G (1985) Intensive induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589
Amadori S, Ceci A, Comelli A, Madon E, Masera G, Nespoli L, Paolucci G, Zaneoco L, Corelli A, Mandelli F (1987) Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204. J Clin Oncol 5: 1356–1363
Creutzig U, Ritter J, Riehm H, Langermann HJ, Henze G, Kabisch H, Niethammer D, Jürgen H, Stollman B, Lasson U (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 65: 298–304
Champlin R, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Mirro, J., Crom, W.R., Kalwinsky, D.K., Santana, V.M., Baker, D.K., Belt, J. (1989). Targeted Plasma Drug Concentration: A New Therapeutic Approach to Relapsed Nonlymphoblastic Leukemia in Children. In: Neth, R., et al. Modern Trends in Human Leukemia VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 32. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74621-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-74621-5_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50967-7
Online ISBN: 978-3-642-74621-5
eBook Packages: Springer Book Archive